

10/551, 648

FILE 'REGISTRY' ENTERED AT 20:11:27 ON 24 JUN 2007
L1 STRUCTURE UPLOADED
L2 6 S L1
L3 172 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:12:29 ON 24 JUN 2007
L4 4 S L3

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPII reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 18 CA/CAplus to be enhanced with pre-1967 CAS Registry Numbers

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 20:11:08 ON 24 JUN 2007

=> file reg
COST IN U.S. DOLLARS
SINCE FILE ENTRY TOTAL
SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 20:11:27 ON 24 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JUN 2007 HIGHEST RN 938512-67-5
DICTIONARY FILE UPDATES: 22 JUN 2007 HIGHEST RN 938512-67-5

10/551,648

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10551648.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 20:11:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1981 TO ITERATE

100.0% PROCESSED 1981 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 36951 TO 42289
PROJECTED ANSWERS: 6 TO 265

L2 6 SEA SSS SAM L1

=> d scan

L2 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-Glucopyranoside, 3-[(4-(1-methylethyl)phenyl)methyl]-1H-indol-4-
yl (9CI)
MF C24 H29 N O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

McIntosh

10/551,648

FULL SEARCH INITIATED 20:12:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40488 TO ITERATE

100.0% PROCESSED 40488 ITERATIONS
SEARCH TIME: 00.00.02

172 ANSWERS

L3 172 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
172.55 172.76

FILE 'CAPLUS' ENTERED AT 20:12:29 ON 24 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 22 Jun 2007 (20070622/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 4 L3

=> d bib abs 1-4 14

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:128524 CAPLUS
DN 144:331622
TI Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2
AU Zhang, Xiaoyan; Urbanski, Maud; Patel, Mona; Cox, Geoffrey G.; Zeck, Roxanne E.; Bian, Haiyan; Conway, Bruce R.; Beavers, Mary Pat; Rybczynski, Philip J.; Demarest, Keith T.
CS Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, 08869, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1696-1701
CODEN: BMCL8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:331622
GI



AB A series of indole-O-glucosides and C-glucosides was synthesized and evaluated in SGLT1 and SGLT2 cell-based functional assays. Glycosides I and II were identified as potent SGLT2 inhibitors and screened in ZDF rats.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1144484 CAPLUS
DN 144:23054
TI Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1
AU Zhang, Xiaoyan; Urbanski, Maud; Patel, Mona; Zeck, Roxanne E.; Cox, Geoffrey G.; Bian, Haiyan; Conway, Bruce R.; Beavers, Mary Pat; Rybczynski, Philip J.; Demarest, Keith T.
CS Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, 08869, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5202-5206
CODEN: BMCL8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
AB A series of benzo-fused heteroaryl-O-glucosides was synthesized and evaluated in SGLT1 and SGLT2 cell-based functional assays. Indole-O-glucoside and benzimidazole-O-glucoside exhibited potent in vitro SGLT2 inhibitory activity.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:120879 CAPLUS
DN 142:219489
TI Preparation of substituted indole-O-glucosides for the treatment of diabetes and Syndrome X
IN Beavers, Mary Pat; Patel, Mona; Urbanski, Maud; Zhang, Xiaoyan
PA Janssen Pharmaceutica N.V., Belg.; Tanabe Seiyaku Co., Ltd; Rybczynski, Philip
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005012243	A2	20050210	WO 2004-US24674	20040730
WO 2005012243	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261664	A1	20050210	AU 2004-261664	20040730
CA 2549025	A1	20050210	CA 2004-2549025	20040730
US 2005037981	A1	20050217	US 2004-903233	20040730
US 7129220	B2	20061031		
EP 1680131	A2	20060719	EP 2004-779672	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
SG 130189	A1	20070320	SG 2007-793	20040730
IN 2006KN01597	A	20070504	IN 2006-KN1597	20060301
US 2006217323	A1	20060928	US 2006-446014	20060602
US 2006229260	A1	20061012	US 2006-453728	20060615
US 2006234954	A1	20061019	US 2006-453727	20060615
US 2006293251	A1	20061228	US 2006-453726	20060615
PRAI US 2003-491523P	P	20030801		
US 2003-491534P	P	20030801		
US 2003-519155P	P	20031112		
US 2004-579758P	P	20040615		

US	2003-519209P	P	20031112
US	2003-519210P	P	20031112
US	2003-519381P	P	20031112
US	2004-579722P	P	20040615
US	2004-579730P	P	20040615
US	2004-579792P	P	20040615
US	2004-903034	A3	20040730
US	2004-903136	A3	20040730
US	2004-903233	A3	20040730
US	2004-903234	A3	20040730
WO	2004-US24674	W	20040730
OS	CASREACT 142:219489;	MARPAT 142:219489	
GI			

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted indole-O-glucosides I, wherein R1 is H, alkyl, amide; R2 is H, F, Cl, alkyl; R3 is H, alkyl, provided that where R3 is alkyl, then R2 is H; Q is CO, (CH2)n; n is 0-2; P is H, acyl, alkoxy carbonyl; Z is substituted or unsubstituted, and is selected from cycloalkyl, Ph, 5- or 6-membered heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicycyl or fused hetero-bicycyl, wherein said fused heterobicycyl has between 1 and 4 heteroatoms independently selected from N, O, and S, were prepared for the treatment of diabetes and Syndrome X. A process is claimed for making a pharmaceutical composition comprising mixing one or more title compds. in combination with a second antidiabetic agent for the preparation of a medicament for treating a condition selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts. Thus, glycoside II was prepared and tested in mice as antidiabetic agent.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:857613 CAPLUS

DN 141:332411

TI Preparation of glucopyranoside compounds having fused heterocycle as SGLT inhibitors

IN Fushimi, Nobuhiko; Yonekubo, Shigeru; Muranaka, Hideyuki; Shionara, Hiroaki; Teranishi, Hirotaka; Shimizu, Kazuo; Ito, Fumiaki; Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 179 pp.

CODEN: PIIXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087727	A1	20041014	WO 2004-JP4009	20040324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004300102	A	20041028	JP 2003-97152	20030331
	CA 2520436	A1	20041014	CA 2004-2520436	20040324
	EP 1609798	A1	20051228	EP 2004-722965	20040324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	CN 1784415	A	20060607	CN 2004-80012295	20040324
	US 2006247179	A1	20061102	US 2005-551648	20050929
PRAI	JP 2003-97152	A	20030331		
	WO 2004-JP4009	W	20040324		
OS	MARPAT 141:332411				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1 = H, halo, etc.; R2 = H, halo, alkyl; R3, R4 = H, OH, etc.; Y = O, S, (un)substituted NH with alkyl, haloalkyl; Q = alkylene, etc.; A = aryl, heteroaryl; G = II, III] were prepared. For example, glycosidation of 6-benzyloxy-4-hydroxy-3-(2-phenylethyl)benzofuran with 2,3,4,6-tetra-O-acetyl-1-O-trichloroacetimidoyl- α -D-glucopyranose in the presence of BF3·OEt2 followed by debenzylation, deacetylation afforded compound IV. In SGLT1 (sodium/glucose cotransporter 1) inhibition assays, the IC50 value of compound IV was 15 nM. Compsd. I are claimed useful for the treatment of diabetes, obesity, etc.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d hitstr 3 14
```


L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 840537-87-3P 840537-89-5P 840537-90-8P
 840537-91-9P 840537-93-1P 840537-94-2P
 840537-95-3P 840537-96-4P 840537-97-5P
 840538-01-4P 840538-05-8P 840538-06-9P
 840538-07-0P 840538-08-1P 840538-09-2P
 840538-10-5P 840538-11-6P 840538-12-7P
 840538-13-8P 840538-14-9P 840538-15-0P
 840538-16-1P 840538-21-8P 840538-22-9P
 840538-24-1P 840538-27-4P 840538-30-9P
 840538-33-2P 840538-36-5P 840538-40-1P
 840538-42-3P 840538-45-6P 840538-58-1P
 840538-81-0P 840538-92-3P 840538-95-6P
 840539-02-8P 840539-04-0P 840539-06-2P
 840539-08-4P 840539-10-8P 840539-12-0P
 840539-14-2P 840539-16-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of substituted indole-0-glucosides as antidiabetic agents and
 for treatment of Syndrome X)
 RN 840537-87-3 CAPLUS
 CN β -D-Glucopyranoside, 3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-1H-indol-
 4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840537-89-5 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-1H-indol-4-yl, 6-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840537-90-8 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-1-methyl-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840537-91-9 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(1,3-benzodioxol-5-yl)ethyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840537-93-1 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840537-94-2 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(2-naphthalenyl)ethyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840537-95-3 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(4-methoxyphenyl)ethyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840537-96-4 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(4-ethoxyphenyl)ethyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840537-97-5 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(4-ethylphenyl)ethyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840538-01-4 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(4-methoxyphenyl)ethyl]-6-methyl-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-05-8 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840538-06-9 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-1H-indol-4-yl,
6-(methyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-07-0 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-1H-indol-4-yl,
6-(ethyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-08-1 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-1H-indol-4-yl,
6-hexanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-09-2 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-methylphenyl)methyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840538-10-5 CAPLUS
CN β -D-Glucopyranoside, 3-[(3-fluoro-4-methylphenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-11-6 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-propylphenyl)methyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840538-12-7 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-(1-methylethyl)phenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-13-8 CAPLUS
CN β -D-Glucopyranoside, 3-((1,1'-biphenyl)-4-ylmethyl)-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-14-9 CAPLUS
CN β -D-Glucopyranoside, 3-[(2-fluoro[1,1'-biphenyl]-4-yl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-15-0 CAPLUS
CN 1H-Indole-1-carboxamide, N,N-diethyl-4-(β -D-glucopyranosyloxy)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-16-1 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 840538-21-8 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-1-methyl-1H-indol-4-yl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 840538-22-9 CAPLUS

CN β -D-Glucopyranoside, 3-[(3-fluoro-4-methoxyphenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 840538-24-1 CAPLUS

CN β -D-Glucopyranoside, 3-[(4-ethoxyphenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 840538-27-4 CAPLUS


CN β -D-Glucopyranoside, 3-[(4-phenoxyphenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-30-9 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-(methylthio)phenyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-33-2 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-chlorophenyl)methyl]-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840538-36-5 CAPLUS
CN β -D-Glucopyranoside, 3-(2-naphthalenylmethyl)-1H-indol-4-yl (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 840538-40-1 CAPLUS
CN β -D-Glucopyranoside, 3-[(2,3-dihydro-5-benzofuranyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-42-3 CAPLUS
CN 1H-Indole, 3-[(4-ethylphenyl)methyl]-4-(β -D-glucopyranosyloxy)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-45-6 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-6-methyl-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-58-1 CAPLUS
CN β -D-Glucopyranoside, 3-[(3-methyl-2-thienyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-81-0 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-(3-pyridinyl)phenyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-92-3 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-2-methyl-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-95-6 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-(3-thienyl)phenyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-02-8 CAPLUS
CN Methanone, (4-ethylphenyl)[4-(β -D-glucopyranosyloxy)-1H-indol-3-yl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-04-0 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-cyclopropylphenyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-06-2 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-(1H-pyrazol-1-yl)phenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-08-4 CAPLUS
CN β -D-Glucopyranoside, 6-chloro-3-[(4-ethylphenyl)methyl]-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-10-8 CAPLUS
CN β -D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-6-fluoro-1H-indol-4-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-12-0 CAPLUS
CN β -D-Glucopyranoside, 3-[(5-ethyl-2-thienyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-14-2 CAPLUS
CN β -D-Glucopyranoside, 3-[(5-propyl-2-thienyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840539-16-4 CAPLUS
CN β -D-Glucopyranoside, 3-[(5-phenyl-2-thienyl)methyl]-1H-indol-4-yl
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 840537-86-2P 840538-04-7P 903552-57-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of substituted indole-O-glucosides as antidiabetic agents and
for treatment of Syndrome X)
RN 840537-86-2 CAPLUS
CN β -D-Glucopyranoside, 3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-1H-indol-
4-yl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 840538-04-7 CAPLUS
CN 1H-Indole-1-carboxamide, N,N-diethyl-3-[(4-methoxyphenyl)methyl]-4-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 903552-57-8 CAPLUS
CN 1H-Indole-1-carboxamide, N,N-diethyl-3-[(4-ethylphenyl)methyl]-4-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4	"7129220"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 20:38
L2	2	"20060247179"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 20:41
L3	2	I1 and prodrug	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 20:55
L4	3	I1 and release	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 21:03
L5	2	2 and alkylene	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 21:42
L6	10	"6683056"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 21:42
L7	25	"6515117"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 21:42

EAST Search History

L8	116609	"607"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 21:42
L9	31	6 7	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/24 21:42